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Background: It remains presently unclear whether disease progression in colorectal carcinoma (CRC), from early,
to invasive and metastatic forms, is associated to a gradual increase in genetic instability and to a scheme of
sequentially occurring Copy Number Alterations (CNAs).
Methods: In this work we set to determine the existence of such links between CRC progression and genetic
instability and searched for associations with patient outcome. To this aim we analyzed a set of 162 Chromosomal
Instable (CIN) CRCs comprising 131 primary carcinomas evenly distributed through stage 1 to 4, 31 metastases and
14 adenomas by array-CGH. CNA profiles were established according to disease stage and compared. We, also,
asked whether the level of genomic instability was correlated to disease outcome in stage 2 and 3 CRCs. Two
metrics of chromosomal instability were used; (i) Global Genomic Index (GGI), corresponding to the fraction of the
genome involved in CNA, (ii) number of breakpoints (nbBP).
Results: Stage 1, 2, 3 and 4 tumors did not differ significantly at the level of their CNA profiles precluding the
conventional definition of a progression scheme based on increasing levels of genetic instability. Combining GGI
and nbBP,we classified genomic profiles into 5 groups presenting distinct patterns of chromosomal instability and
defined two risk classes of tumors, showing strong differences in outcome and hazard risk (RFS: p = 0.012, HR = 3;
OS: p < 0.001, HR = 9.7). While tumors of the high risk group were characterized by frequent fractional CNAs, low
risk tumors presented predominantly whole chromosomal arm CNAs. Searching for CNAs correlating with negative
outcome we found that losses at 16p13.3 and 19q13.3 observed in 10% (7/72) of stage 2–3 tumors showed strong
association with early relapse (p < 0.001) and death (p < 0.007, p < 0.016). Both events showed frequent co-occurrence
(p < 1x10-8) and could, therefore, mark for stage 2–3 CRC susceptible to negative outcome.
Conclusions: Our data show that CRC disease progression from stage 1 to stage 4 is not paralleled by increased levels
of genetic instability. However, they suggest that stage 2–3 CRC with elevated genetic instability and particularly
profiles with fractional CNA represent a subset of aggressive tumors.
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Genetic instability is a hallmark of cancer cells and has
been proposed to act as a catalyst of cancer development
from early stages on [1,2]. It is generally agreed that
tumor progression occurs according to a scheme of
gradual accumulation of genetic anomalies and that gen-
etic instability is highest in most aggressive and meta-
static forms of the disease. In colorectal cancer (CRC),
genetic instability is subdivided into three classes; (i)
mismatch repair deficiency (MIN), often of hereditary
origin but also sporadically acquired, associated with
base slippage mostly at poly(A) or poly(C) tracks and
near diploid genomes, 15% of CRC (ii) chromosomal
instability (CIN) resulting in severely rearranged karyo-
types and aneuploidy, 65% of CRC (iii) non-MIN/non-
CIN showing a methylator phenotype, 20% of CRC [3].
Major genetic mutations found and acting as key events
in CRC, affect the WNT/APC/CTNNB1, KRAS/BRAF,
FBXW7, PTEN, SMAD4, TGFBRII, and TP53 genes [4,5].
Interestingly, patterns of mutated genes vary according
to the class of CRC. BRAF mutations seem prevalent in
MIN, whereas TP53 mutations are essentially found in
CIN. Interestingly, genes promoting DNA repair, DNA
damage checkpoint as well as translesional DNA replica-
tion are mostly down-regulated in CRC tumors com-
pared to proliferating normal adjacent tissues, probably
favoring the overall genetic instability at the nucleotide
level [6]. In addition to these functionally validated aber-
rations, CGH based studies have identified widespread
copy number alterations (CNA), some of which highly
recurrent. Typical CNA patterns in CRC involve gains at
8q, 13q and 20q as well as losses at 5q, 8p, 17p and 18q
[7]. These observations were confirmed in higher reso-
lution array-CGH analyses and the boundaries of these
regions of CNA defined with greater precision. More-
over, a number of focal events were pointed out [8]. The
number of genetic anomalies linked to CRC pathogen-
esis is elevated and has risen with recent large scale
sequencing efforts [9]. However, questions remain as to
the role of widespread chromosomal instability in the
course of the disease, in particular how these relate to
progression of CRCs and patient relapse.
Although the sequential order originally proposed by
Fearon and Vogelstein for CRC progression has been
disputed the overall model is still regarded as valid [10].
Stepwise progression from normal epithelium, through dys-
plasia to carcinoma builds on a gradual accumulation of
genetic anomalies. Recent work showed that copy number
alterations (CNA) set in early in adenomas and reached in
progressed adenomas a level similar to that found in carcin-
omas [6,11]. It has also been suggested on the basis of a
meta-analysis of chromosome CGH [7] and array-CGH [8]
that progression from invasive cancer to metastasis was
accompanied by an increase in the number of CNAs.However, no clear cut results were proposed ascertain-
ing the existence of a molecular progression scheme be-
tween early carcinoma (stage 1), invasive (stage 2 and 3)
and metastatic (stage 4) CRC. In this work we wanted to
verify whether we could relate CRC progression (from
stage 1 to stage 4 and, eventually, to distal metastasis) to
a gradual increase of genetic instability and sketch out a
sequence of CNA increment. Moreover, we wanted to
determine whether genetic instability correlated with
patient outcome. To this aim we analyzed a set of 162
CIN CRCs comprising 131 primary carcinoma evenly
distributed through stage 1 to 4 and 31 metastases (28/
31 formed a primary-tumor/matched-metastasis pair)
and 14 adenomas by array-CGH. Our data showed that
stage 1, 2, 3 and 4 tumors did not differ significantly at
the level of their CNA profiles. This led us to ask
whether the level of genomic instability, as illustrated by
array-CGH, was linked to disease outcome. Based on the
Global Genomic Index (GGI), which corresponds to the
fraction of the genome involved in CNA and the number
of breakpoints (nbBP), which were determined as chromo-
somal sites where copy number shifts occurred, we defined
two classes of tumors showing strong differences in out-
come and hazard risk. CNAs correlating with early relapse
or death in stage 2 or 3 patient were searched and two re-
gions of copy number loss could be selected due to their
strong association to negative outcome.
Methods
Patient and tumor samples
Genomic profiles were established on 176 samples: 14
adenomas, 131 primary carcinoma and 31 synchronous
(9) or metachronous (20) metastases (among which 28
were paired to their primary tumor). Biological samples
were collected in 4 clinical centers of south-west France:
Bergonié Institute, Bordeaux; CHU Dupuytren, Limoges;
CRLC Val d’Aurelle, Montpellier; Purpan Hospital,
Toulouse between 1993 and 2008. Clinical data and
follow-up information were collected. Data were anon-
ymized. This project was submitted to the ethics com-
mittees of the respective clinical centers participating
to the study and was approved by the National Insti-
tute of Cancer (INCa) following the recommendations
of the French National Authority for Health (FNAH).
Patient samples were processed according to French
Public Health Code (law n°2004-800, articles L. 1243–4
and R. 1243–61) and the four biological resources
center has received the agreement from the French au-
thorities to deliver samples for scientific research. The
authorization numbers were AC-2008-812 (Bergonié),
AC-2007-34 (Dupuytren), AC-2008-700 (Val d’Aur-
elle), AC-2008-820 (Purpan). Before surgery patients
are informed that their surgical specimens can possibly
be used for research purposes. They can refuse this
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this case tumor biopsies were destroyed.
Clinical characteristics are summarized in Table 1 and
further detailed in Additional file 1. Adenomas and car-
cinomas were surgically removed and immediately fro-
zen at − 80°C. Only samples containing more than 50%
of tumor cells were included in the study. Samples were


































Variables GGI median [range] 0.12 [0.03
nbBP median [range] 65.5 [
Abbreviations: TNM Tumor Node Metastasis staging UICC/AJCC 6th edition, GGI Glob
nbBP number of breackpoints; RFS relapse-free survival, OS overall survival.marker analysis and were all MIN negative. Four (4) pa-
tients (TNM stage 4) received a treatment prior to
surgery.
DNA extraction
Genomic DNA was extracted using QIAmp DNA mini
kit (Qiagen, Courtaboeuf, France). Each DNA sample
was quantified by nanospectrophotometry (NanoView,lorectal cancers included in the study
mas Carcinomas-primary tumors
N=14 % N=131 %
6 42.9 39 30.2
8 57.1 90 69.8
0 2
9 64.3 75 57.3
5 35.7 56 42.7
4 28.6 7 5.4
5 35.7 47 36.4
4 28.6 31 24.1
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agarose electrophoresis.
TP53 mutation
TP53 mutation status was determined in 98 samples by
sequencing 3 PCR fragments containing exons 5 to 9
(Genoscreen, Lille, France). PCR reactions were done
using BDT v3.1 kit in a DNA thermocycler PCR 9700
(Applied Biosystems, Villebon-sur-Yvette, France). Each
sample was sequenced on both sense and antisense strands
on a 96-capillary 3730xl DNA Analyzer. PCR primers used




TG, >P53_ex8-9-F: CAAGGGTGGTTGGGAGTAGA, >P
53_ex8-9-R : TGTCTTTGAGGCATCACTGC.
Mutation detection was then done by sequence align-
ment and comparison to the Genebank reference se-
quence NC_000017 (7512445..7531642) using Multalin
(http://bioinfo.genotoul.fr/multalin/). Each mutation was
validated using the mutation validation tool available on
IARC TP53 database (http://www-p53.iarc.fr/).
Array-CGH
The 176 DNA samples were analyzed on two generations
of Integragen BAC-arrays (Integragen, Evry, France) IgV6+
(5015 BACs), IgV7 (5878 BACs), with a median resolution
of 0.6 Mb. BACs were spotted in quadruplicate. DNA label-
ing and hybridization, were done as previously described
[12] with slight modifications: 600 ng of DNA were labeled
with BioPrime Total Genomic Labeling System (Invitrogen
SARL, Cergy Pontoise, France). Arrays were scanned using
Axon 4000B scanner (Molecular Devices, CA, USA) and
images were analyzed using Genepix 6.0. Data were ana-
lyzed in web-based platform for copy number array man-
agement and analysis (http://bioinfo-out.curie.fr/CAPweb/).
Normalized and replicates filtered data were exported as
text file for further analyses. In order to analyze all the data
from different Integrachip versions, we used the Nexus 6.0
Software (Biodiscovery, El Segundo, CA, USA). Analysis
settings for data segmentation and calling were the follow-
ing: significant threshold for Rank Segmentation algorithm:
0.005, Max Continuous Probe Spacing: 6000, Min number
of probes per segment: 6, high level gain: 0.485, gain, 0.138,
loss:-0.153, homozygous copy loss:-0.73. Nexus 6.0 Soft-
ware was used to calculate frequency plots, factor enrich-
ment (significantly overrepresented factor values in a
particular factor group identified using the two tailed
Fisher’s Exact test at a p-value of p < 0.05), significant
chromosomal differences between two groups (comparison
tool: two tailed Fisher’s exact test with p-value < 0.005 and
minimal frequency difference set at 10%) and Survival Pre-
dictive Power (log-rank test is used to identify genomicregions yielding a high degree of survival prediction; p-value
is calculated by permuting the survival time for each sample
and comparing the log-rank statistic for the permuted data
to the original data; threshold used was p-value < 0.05).
Genomic quantitative variables calculation
An R script using Circular Binary Segmentation (CBS)
algorithm implemented in DNAcopy (Bioconductor for R)
and normalized/replicates filtered data as input, were used
to determine genomic metrics such as gains, losses, high
level gains, homozygous copy losses. For this purpose, the
thresholds were as used in Nexus 6.0 analysis (high
level gain: 0.485, gain, 0.138, loss:-0.153, homozygous
copy loss:-0.73). The GGI was calculated at a probe
level as follows: (number of probes gained + number of
probes lost) /number of informative probes. The GGI
corresponds to the fraction of the genome involved
in CNA. The nbBP was determined as the number of
transitions or breakpoints in the genomic profiles after
smoothing and segmentation of the data. The R script
is available upon request.
Statistical analyses
Continuous variables were presented as medians and
range, and compared between populations with the
Kruskal-Wallis test. Categorical variables were presented
using contingency tables and compared with Pearson’s
chi-square test or Fisher’s exact test. Differences were
considered statistically significant when p < 0.05. Classes
of genetic instability were defined using two quantitative
variables as metrics: Global Genomic Index of alteration
(GGI) and number of breakpoints (nbBP). First on the
whole set of data (n = 176), GGI and nbBP were grouped
into three classes using the 33th percentile (first tercile)
and the 66th percentiles (second tercile). Then, for stage
2 and 3 set of data (n = 72), number of BP was grouped
into two classes, low (<116) and high (>116). Using ROC
curves (see Additional file 2) the optimal nbBP thresh-
old was calculated to maximize the Youden’s index
(sensitivity and specificity minus 1) which induces the
best discrimination according to vital status. Statistical
associations between GGI or nbBP were calculated
using the nonparametric test for trend across ordered
groups. To account for multiple testing, the statisti-
cally significant threshold was set at 0.01.
Overall survival (OS) was the primary endpoint for this
study and was calculated from the date of surgery until the
date of death. Relapse-free survival (RFS) was the secondary
endpoint and was calculated from the date of surgery until
the date of relapse. Patients who died without relapse were
censored at the time of death. Patients lost to follow-up
were censored at the time of last visit. The Kaplan-Meier
method was used to estimate OS and RFS. Survival rates
were compared using log-rank test.
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ate analysis and were included into a multivariate Cox pro-
portional hazards model. Using the model, a score was
allocated proportional to the regression coefficients. The
adjacent non-significant categories were regrouped in
order to reduce the number of prognostic categories (see
Additional file 3). Hazard rate (HR) and its 95% confidence
interval (95% CI) were calculated using Cox model.
Statistical analyses were performed with GraphPad
Prism 5 (www.graphpad.com) and STATA software 11.0
(StatCorp. 2009. Stata: Release 11. Statistical Software.
College Station, TX: StataCorp LP).
Results
Outcomes in our colorectal cancer set
Median follow-up was 48.4 months (range: 1 to
115 months). Median overall survival was not reached.
Three-year relapse-free survival (RFS) was 69% (95%
CI: 55–79) and 5-years overall survival (OS) was 66%
(95% CI: 51–78).
Copy number alterations in our colorectal cancer set
Genomic profiles were established on our set of 176
colorectal tumors by CGH on BAC-arrays comprising
3000 to 5800 clones (mean resolution 1 to 0.6 Mb). Our
sample set corresponded to 14 adenomas, 131 primary
tumors and 31 distal metastases. All these CRC samples
were selected as microsatellite stable. Overall CNA pro-
files in our set of tumors were in harmony with those
described by others ([8,13]) (Figure 1A). Most commonly
altered regions (gains or losses in > =35% of the samples)
were gains at chromosomes 7p, 7q, 8q, 13q, 20 and
losses at 8p, 17p and 18 (Figure 1A, Additional file 4).
High-level gains (HLG) (log2ratio > 0.485) were observed
throughout the whole genome. However, only HLGs
located at 7p21.3-p11.2, 8q11-q24.3, 13q11-q34 and
20p13-q13.33 occurred in more than 5% of the tumors.
Stratification of CNA profiles and genetic instability
according to disease stages
We wanted to determine the existence of copy number
changes correlated to disease progression from aden-
omas to carcinomas and from superficial (stage 1) to in-
vasive (stage 2 and 3) and metastatic cancer (stage 4 and
metastases). To this aim, we stratified CGH profiles ac-
cording to disease stages and metastases (Figure 1B).
Adenomas clearly differed from carcinomas showing less
rearranged profiles. This indicated that the transition
from benign to malignant tumors was accompanied by a
sharp increase in genetic instability. Contrastingly and
interestingly, cumulative CNA profiles of stage 1, 2, 3,
4 carcinomas and distal metastases appeared globally
similar. To identify regions of CNA associated to the pro-
gression from one disease stage to another, we performedpairwise comparisons (adenomas vs. stage 1 carcinomas,
stage 1 vs. stage 2, 2 vs. 3, 3 vs. 4 and metastases vs. associ-
ated primary tumors) (Figure 1C and Additional file 5).
Most significant changes were seen between adenomas and
stage 1 carcinomas, with gains at 8q, 13q, 20 and losses at
8p, 15p, 17p and 18q. Changes associated to stage transi-
tion (1 to 2, 2 to 3, 3 to 4) could be found, but were difficult
to relate to a coherent scheme of progression. This was
exemplified by losses at chromosome 14 and 15, associated
to transition from stage 2 to 3 and from stage 3 to 4
(Figure 1C). Both events were present in stage 2 and
absent in stage 3. Strangely, their occurrence went
back up in stage 4. This was not consistent with a cu-
mulative progression scheme, in which tumors pro-
gress sequentially from stage 2 to stage 3 and end up
progressing to stage 4.
Next, we verified whether the level of genetic instability
increased according to disease stage using two metrics,
Global Genomic Index (GGI), and the number of break-
points (nbBP) (as defined in the Materials and Methods
section). Median levels [range] of GGI and nbBP in the
whole dataset were 0.35 [0.03 – 0.64] and 81 [33 – 203] re-
spectively. It was apparent that genetic instability increased
significantly between adenomas (AD) (GGI = 0.12/nbBP =
65.5), primary tumors (PT) (GGI = 0.35 / nbBP: 76) and
metastases (MT) (GGI: 0.43 / nbBP: 105); (AD vs PT p =
0.0001, PT vs MT p= 0.005) (Figure 2A, B), but did not
change significantly from stage 1 to 4 carcinomas
(Figure 2C, D). We delineated classes of genetic in-
stability based on GGI or nbBP terciles and were in-
trigued to see that stage 2 and 4 presented a large
proportion of GGI-high and/or nbBP-high tumors,
while stage 1 showed a prevalence of low instability
tumors (see Additional file 6A, B). Moreover, we noted
that the nbBP was higher in younger patients (<60y,
p = 0.013) and lower in rectal cancers (p = 0.032), irre-
spective of TNM stage (Figure 2E-F). However, GGI
and nbBP levels did not differ significantly between
TP53 wild type and their mutated counterparts.
Genetic instability and outcome of the disease
While different stages of CRC could not be clearly
distinguished by their cumulative CNA profiles, it was
noticeable that individual tumors showed important dif-
ferences in genetic instability, some tumors presenting
highly rearranged genomes and others only limited num-
bers of anomalies. This prompted us to determine
whether the level of genetic instability could be related
to disease outcome. Because stage 1 tumors are associ-
ated to a very limited number of recurrence and stage 4
to negative outcome we focalized our analysis on the 72
stage 2 and 3 CRCs present in our dataset (17.5% stage 2
and 40.5% stage 3 CRC patients will eventually show dis-
ease progression at 5 years) [14] (see Additional file 7).
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nbBP that were best fitted to define a group of bad out-
come. This defined 2 classes, nbBP-low (<116) and
nbBP-high (> = 116). The latter was associated to bad
outcome in both RFS (p = 0.02) and OS (p = 0.001) (seeFigure 1 Copy number alteration (CNA) patterns. Gains are shown in g
white and blue vertical areas. A: CNA frequency plot in the complete tumo
threshold. B: CNA frequency plots in different disease stages: Ad: adenoma
Stage 3 Primary Tumors, S4PT: Stage 4 Primary Tumors, MT: metastases. C:
assMT: depicts metastases associated to its cognate primary tumor.Additional file 8A, B). For GGI, three classes were de-
fined (low, medium, high) according to terciles. Best
prognosis was found with GGI-low (<0.25) and worst
prognosis with GGI-median [0.25-0.41]. Unexpectedly,
GGI-high (≥0.41) tumors presented an intermediatereen and losses in red. Boundaries of chromosomes are indicated by
r set. The grey horizontal bar indicates the 35% of tumors affected
s, S1PT: Stage 1 Primary Tumors, S2PT: Stage 2 Primary Tumors, S3PT:
significant differences between sequential steps of disease progression.
Figure 2 Distribution of genomic instability as defined by the GGI and nbBP metrics in different groups of colorectal tumors. A: Boxplots of GGI
values in adenoma, primary CRC and metastases. B: Boxplots of nbBP values in adenoma, primary CRC and metastases. C: Boxplots of GGI values in the 4
stages of CRC: stage 1 (S1PT), stage 2 (S2PT), stage 3 (S3PT), stage 4 (S4PT). D: Boxplots of nbBP values in the 4 stages of CRC: stage 1 (S1PT), stage 2 (S2PT),
stage 3 (S3PT), stage 4 (S4PT). E: Boxplots of nbBP values in different location of colon cancer (left colon, right colon and rectum). F: nbBP boxplots
stratified on patient age.
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vs > =0.41, p = 0.1530; <0.25 vs [0.25, 0.41], p = 0.0220;
OS: <0.25 vs > =0.41, p = 0.3843 ; [0.25, 0.41] vs > =
0.41, p = 0.0074 ; < 0.25 vs [0.25, 0.41], p = 0.002), see
Additional file 8C, D). A multivariate Cox proportional
hazards model was built based on the combination of
GGI and nbBP. This model produced 6 groups (G1 to
G6), of which only 5 were useful (G2 was empty)
(Figure 3A). Using weights of the regression coeffi-
cients, we delimited 3 groups of high risk (G3, G4, G6)
and 2 groups of low risk (G1 and G5). We combined
all high risk and all low risk groups in one high and
one low risk class, which showed clear differences
in outcome (RFS: p = 0.012, OS: p < 0.001 Figure 3B,
C) and Hazard Ratio using either relapse free (HR =
3) or overall survival (HR = 9.7) as an endpoint
(Table 2).CNAs associated to bad outcome in stage 2 and stage 3 CRCs
The above described risk classes were based on quantita-
tive criteria (GGI and nbBP) defining levels of genetic
instability in CRC. The different subgroups that were de-
fined thus presented different levels of genetic instability
(see Additional file 9A). However, while G4 (nbBP-High/
GGI-median) and G5 (nbBP-Low/GGI-High) respect-
ively belonged to the high and low risk class, their aver-
age numbers of gains, high level gains and losses were
similar (Additional file 9B,C). This contrasted with G6
which bore distinctly higher numbers of CNAs.
These results prompted us to search for qualitative dif-
ferences that may explain the differences in risk of re-
lapse and death. We, thus, searched for specific copy
number changes between high and low risk classes of
CRCs, aiming at the definition of markers of relapse in
stage 2 and 3 colorectal cancer.
Figure 3 Genomic instability risk groups in stage 2 and 3 CRCs. Death and risk of relapse were correlated to genomic instability variables.
A: Scatter plot integrating nbBP and GGI metrics. Three classes were determined for GGI:low (<0.25), intermediate ([0.25; 0.41[) and high (≥0.41)
levels, with high risk associated to intermediate GGI, whereas two classes were defined for nbBP (<116 vs ≥116), with high risk being associated
to high number of breakpoints. This produced 6 groups of risk of which one was empty. Tumors within high risk groups are shown as red dots,
low risk as blue dots. B: Relapse free survival according to risk groups. C: Overall survival according to risk groups. Red curves correspond to the
high risk, blue curves to low risk group.
Table 2 Survival rates according to prognostic categories
RFS
No. of relapse 3-year RFS rate (%) HR 95% CI
Low risk 8/37 82.6 1
High risk 15/35 49.8 3.0 [1.2;7.2]
OS
No. of death 5-year OS rate (%) HR 95% CI
Low risk 3/37 87.9 1
High risk 16/35 39.1 9.7 [2.8;34.0]
Abbreviations: RFS relapse-free survival, OS overall survival, HR hazard ratio.
CI confidence interval.
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searched for significant differences in the high and low
risk classes. Using the comparison tool of Nexus 6.0
software package we compared chromosomal regions of
the high (n = 34) and low risk (n = 38) classes using two-
tailed Fisher’s Exact test and identified 29 differentially
represented genomic regions (see Additional file 10).
Second, we used the Survival Predictive Power tool of
Nexus in order to determine gains and losses signifi-
cantly correlated with poor survival in the subset of
stage 2 and 3 primary CRCs producing a list of 31 gen-
omic regions (see Additional file 10). Losses at 16p13.3
and 19q13.3 were selected in both approaches and
Orsetti et al. BMC Cancer 2014, 14:121 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/121presented the strongest correlation (p < 0.001) to RFS
and OS (p = 0.007, p = 0.016 Table 3, Figure 4A-D).
Losses at 16p13.3 and 19q13.3 showed significant co-
occurrence. All samples with 16p13.3 loss showed con-
comitant 19q13.3 loss (p < 1×10-8), thus signing for a
group of CRC with negative outcome (see Additional file
11). This correlation remained significant in a subset of
stage 2 CRCs (not shown). It was noticeable that CNAs
at 16p13.3 and 19q13.3 were not restricted to losses and
included a sizeable fraction of gains. However, only
losses were associated to negative outcome, whereas
gains had either no impact on survival risk (16p13.3) or,
on the contrary for 19q13.3, were associated to favorable
outcome (Figure 4C). This yin-yang correlation led us to
investigate whether losses at 19q13.3 were enriched in
high risk groups, while gains were more frequent in low
risk groups. Indeed, we found that losses at 19q13.3 were
enriched in the high risk group 6 (p = 0.0035), whereas
gains were prevalent in low risk group 5 (p = 0.0025)
(see Additional file 12).
In a second time, we tested in our stage 2 and stage 3
dataset the prognostic significance of focal regions and
genes that were previously described in the literature
[8,15,16]. Gains and losses were determined for each re-
gion bearing these target genes and association with RFS
and OS tested. Significant association with short survival
was found for only 5/87 genes, namely SMAD4 (p =
0.0045), CCDC68 (p = 0.0054), TCF4 (p = 0.0054), RAX
(p = 0.0047) located on chromosome 18q21.2-21.3 and
TSKS (p = 0.005) located on chromosome 19q13.3. Previ-
ously proposed prognostic regions such as losses at 4p,
4q22-q35, 5q, 6q, 8p, 13q ,14q, 15q, 17p, and gains at 8q,
10q, 20q were not found significantly associated with either
RFS or OS in our series of stage 2 and 3 tumors [8,15-18].Table 3 Survival rates according to genomic regions



















285 genes Loss 8 (11.3%) 4 5.04
Missing 1
p*= 0.003
Abbreviations: RFS relapse-free survival, OS overall survival, HR hazard ratio, CI confidDiscussion
In this work, using array-CGH as an analytical approach,
we aimed at determining whether genetic instability was
related to progression of colorectal cancer and verify
whether it could be used as a prognostic indicator. Colorec-
tal cancer has served as a model of stepwise progression
from normal epithelium, through benign growth, into ma-
lignant cells that eventually become invasive and acquire
metastatic properties [5]. We were interested in determin-
ing the existence of a progression scheme between superfi-
cial carcinomas (stage 1), invasive carcinomas (stage 2 and
3) and metastatic carcinomas (stage 4) based on a gradual
accumulation of genomic alterations, with alterations oc-
curring specifically at each step of progression.
Main regions of gain and loss observed in this work
were concordant with previously reported observations
on CRC [8,13]. Our data showing a marked increase in
the number of CNAs in the transition from adenomas to
carcinomas are in concordance with previously reported
array-CGH work on early and advanced colorectal aden-
omas [11]. Most significant changes between adenomas
and stage 1 CRCs were the occurrence of gains at 8q,
13q, 20 and losses at 8p, 15p, 17p and 18q in keeping
with published works [7,11,19]. However, in contrast to
Diep and coworkers [7] who proposed that transition
from Duke’s B to C stage was associated to increased oc-
currence of gain at 1q and that Duke’s C to D to that of
gains at 20q and Xq and loss at 21q, we could not iden-
tify CNAs whose occurrence was assigned to the transi-
tion from one stage to the next. This was exemplified by
loss at chromosomes 14 and 15 which were present in
stage 2, absent in stage 3 and present again in stage 4.
We found that the number of CNAs in metastases was





death HR 95% CI
5-year OS
rate (%)
72.8 11 1 71.8
[0.43;3.41] 73.7 4 1.05 [0.33;3.31] 62.7
[3.10;38.6] 0 4 5.33 [1.63;17.5] 22.2
p**< 0.001 p*= 0.05 p**= 0.007
66.8 12 1 66.7
[0.02;1.30] 91.7 3 0.77 [0.22;2.75] 80.4
[1.55;16.4] 26.3 4 4.36 [1.33;14.2] 23.8
p**<0.001 p*= 0.07 p**= 0.016
ence interval, *, Likelihood ratio test; **, log-rank test.
Figure 4 Relapse free and overall survival according to CNA at 16p13.3 and 19q13.3 in stage 2 and 3 CRCs. Losses at both locations are
associated to shortened disease free and overall survival. Interestingly, gains at 19q13.3 appear to be protective for RFS. A: Relapse free survival according
to CNA at 16p13.3. B: Overall survival according to CNA at 16p13.3. C: Relapse free survival according to CNA at 19q13.3. D: Overall survival according to
CNA at 19q13.3. Red curves correspond to gain, green curves correspond to loss, and blue curves correspond to absence of CNA.
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ses, we detected small regions of gains on chromosome
1q, 6p21, 10p and 17q21 and loss at chromosome 8p12
that occurred more frequently in metastases than in pri-
mary tumors (see Additional file 5). However, we could
not infer the existence of anomalies specifying metastatic
invasion as previously proposed [20]. Along similar lines
we could not determine differences in CNA profiles be-
tween TP53 wild type and mutated tumors [8]. The ab-
sence of specific changes associated to the TP53 status
in our dataset may be related to sampling differences. As
a matter of fact, our series was restricted to CIN CRCs,
while that in the work by Sheffer and colleagues (2009)
comprised MSI cases that show TP53 mutations at a
lower frequency and present fewer CNAs and at differ-
ent locations than in CIN tumors [21].We could not associate any qualitative change of CNA
to disease progression, but the increase of genetic in-
stability between stage 1 and stage 4 tumors and be-
tween primary CRCs and metastases suggested that the
global level of genetic instability could be of clinical or
prognostic significance in CIN colorectal cancer. We
were interested to note that whereas genetic instability
was lowest in stage 1 and highest in stage 4 CRC, its
level in stage 2, genetic instability was in keeping with
that in stage 4. Taken together, our data were not con-
sistent with a model where CRCs progress gradually
from stage 1 to stage 4, because of the resemblance of
CNA profiles and genetic instability levels in stage 2 and
stage 4 tumors. This similarity suggested that a large
part of stage 4 may arise directly from most unstable
stage 2 tumors. The difficulty to define a progression
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disease stages may be related to the fact that CRC sta-
ging is a clinical progression scale which takes local and
distal invasion into account and no tumor intrinsic
characteristics.
We, hence, asked the question of whether the level of
genetic instability could be a prognostic indicator in
stage 2 and 3 CRCs. Using the fraction of the genome
involved in CNA (GGI) and the number of breakpoints
(nbBP) detected in the array-CGH profiles, we defined 5
groups of CRC. These groups differed in their level of
genetic instability, but also their profile of anomalies. In-
deed, tumors with low nbBP presented CNA involving
large chromosomal regions (whole chromosomes or
chromosomal arms), whereas those with elevated nbBP
showed fractional gains or losses. The group with the
lowest instability (low-GGI/low-nbBP) was expectedly
associated to good prognosis, whereas those with high-
nbBP correlated with increased risk of relapse or short-
ened overall survival in stage 2 and 3 CRCs. Our results
suggest that genetic instability could be an interesting
tumor specific prognostic variable in CIN colorectal can-
cer. Along similar lines, Poulogiannis and coauthors [17]
defined 4 groups of instability in CRC, with low levels of
instability associated with good outcome and high levels
with bad prognosis. It is of note that this study was per-
formed on a series comprising both MSI and MSS CRC
and it is likely that their group of low instability was
largely composed of MSI cases, which are of better prog-
nosis than MSS. Other studies have proposed to relate
genetic CNA patterns to outcome [22] or response to
chemotherapy [13]. Remarkably, in our study the group
presenting an elevated fraction of the genome involved
in CNA, but low breakpoint numbers (high-GGI/low-
nbBP), was the other group associated with low risk.
This group was representative of tumors with large regions
of CNA or whole chromosomal arm copy variations and
contrasted in terms of prognosis with tumors with high-
nbBP which were of bad prognosis. These results were
reminiscent of observations by Janoueix-Lerosey et al., [23],
who showed that in neuroblastoma tumors with whole
chromosome CNA displayed good survival, while those
with fractionated CNA presented a high risk of relapse.
These data led us to search for specific copy number
changes correlated to the bad outcome groups. To this
aim we used two convergent strategies to identify re-
gions of CNA correlated to adverse outcome in our
stage 2 and 3 series. Copy number loss at 19q13.3 and/
or 16p13.3 was clearly associated to worsened disease
course, as shown by strong correlation with either short-
ened RFS or OS in stage 2 and 3 tumors. The 16p13.3
region has already been described as a prognostic region
in CRC [15]. This region bears a total of 167 known
genes among which AXIN1 appears a serious candidateas it had been shown to be mutated in colorectal cancers
and wild-type axin 1 can induce apoptosis in colorectal
cancer cells [24,25]. The 19q13.3 region comprises 285
genes and among them the BAX pro-apoptotic gene and
the polymerase delta gene POLD1. Low expression of
BAX protein in stage 3 colorectal cancers has been
linked to shorter RFS and 5-FU-based treatment resist-
ance [26]. POLD1 deletion could be involved in impaired
DNA replication generating breaks and high rate of mu-
tations [27]. As 16p13.3 (AXIN1) and 19q13.3 (BAX) are
frequently co-deleted in our high risk group, apoptotic
pathway in these tumors could be severely impacted giv-
ing significant resistance to apoptosis and growth advan-
tage in malignant cells of these tumors. It was of note
that we could confirm the association with adverse out-
come for only 5/87 genes whose gain or loss had been
previously shown to be of prognostic significance. Simi-
larly, a large number of prognostic gains or losses could
not be confirmed in our dataset [8,15-18].Conclusions
CNA profiles in CIN CRC are not consistent with the con-
ventional scheme stating a stepwise progression from stage
1 to stage 4.
The level and pattern of genetic instability has been
found to correlate with disease outcome, as tumors
with fractionated gains and losses were of worse prog-
nosis than tumors showing low breakpoint levels.
We identified that recurrent loss at 16p13 and 19q13
were significantly associated to bad outcome in stage 2
and 3 CRCs. Both regions were co-occurring in the high
risk genetic instability groups.Additional files
Additional file 1: Detailed patients and samples characteristics.
Additional file 2: ROC curve and determination of Youden’s index
for nbBP in stage2 and 3 CRCs. The optimal nbBP threshold was
calculated using ROC curves to maximize the Youden’s index which
induces the best discrimination according to vital status.
Additional file 3: Multivariate Cox Model and score establishment.
Additional file 4: Gain and loss regions found in more than 35% of
the tumors.
Additional file 5: Regions of CNA differentially represented in CRC
disease stages.
Additional file 6: GGI (A) and nbBP (B) tercile distribution in clinical
stages of 131 primary CRCs. The GGI or nbBP values distribution were
cut in terciles and the fraction of CRCs belonging to this tercile was
plotted in Y axis for each clinical stage. S1: stage 1, S2: stage 2, S3: stage
3, S4: stage 4. The first tercile was colored in yellow, the intermediate one
in orange and the last one in red. Stage 2 and 4 presented a large
proportion of GGI-high and/or nbBP-high tumors, while stage 1 showed
a prevalence of low instability tumors.
Additional file 7: Overall survival curves for the TNM stages of
primary CRCs (n=129). Stage 1 (black curve), Stage 2 (red curve), Stage
3 (blue curve) and Stage 4 (green curve).
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http://www.biomedcentral.com/1471-2407/14/121Additional file 8: Relapse free survival and overall survival in stage
2 and 3 CRCs (n=72) according to nbBP groups and GGI groups.
nbBP groups were calculated using ROC curves (A,B) (nbBP<116; nbBP>=116;
RFS (p=0.02), OS (p=0.001)) and GGI groups were determined according to
distribution terciles (C,D) (GGI<0.25; GGI [0.25-0.41]; GGI>=0.41) (RFS: <0.25
vs >=0.41, p=0.3287; [0.25, 0.41] vs >=0.41, p=0.1530; <0.25 vs [0.25, 0.41],
p=0.0220; OS: <0.25 vs >=0.41, p=0.3843; [0.25, 0.41] vs >=0.41, p=0.0074;
< 0.25 vs [0.25, 0.41], p=0.002).
Additional file 9: Genomic groups characterization in stage 2 and
3 CRCs (n=72). Gains are shown in green and losses in red. Boundaries
of chromosomes are indicated by white and blue vertical areas. A:
Frequency plots of CNA along the genome for the 5 genomic groups
(G1, G3, G4, G5, G6) as defined in Figure 3. The high risk groups are G3/
G4/G6 and the low risk groups G1/G5. B: Average number of regions of
gains (green bars) and regions of losses (red bars) according to genomic
group. G6 bore distinctly higher numbers of CNAs. C: Average number of
high level regions of gain (green bars) and homozygous copy loss (red
bars) according to genomic groups. G3 did not show homozygous copy
loss in our series and despite a moderate GGI, G4 presented a number of
high level gains similar to G5 and G6.
Additional file 10: Regions of CNA significantly associated to
negative outcome in stage 2 and 3 CRCs. Two lists were obtained
using complementary approaches: 1- Comparison tool giving significant
chromosomal regions in high and low risk classes using two tailed
Fisher’s Exact test (p-value <0.005). 2- Analysis using the Survival
Predictive Power package in the Nexus 6.0 genomic analysis software
(perm p-value< 0.05). Two regions of loss were selected in both
analyses and are highlighted in the list.
Additional file 11: Whole genome CNA frequency plots of stage 2
and 3 (n=72) CRC samples according to 19q13.3 CNA (gain, loss or
no copy number changes). Gains are shown in green and losses in red.
Boundaries of chromosomes are indicated by white and blue vertical
areas. Chromosome 16 and 19 are delimited by a black rectangle
showing co-occurrence of 19q13.3 and 16p13.3 losses.
Additional file 12: 19q13.3 gains occur preferentially in risk group
G5, whereas 19q13.3 losses correlate with high risk group G6.
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